NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**CONFIDENTIAL**

## Demo Report

**Report Issued** 03/30/2020 13:22
**Last Report Issued** 01/19/2015 11:53

**88888**
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

**Patient Name** 4125SP-POS
**Patient ID** 4125SP-POS
**Chain** 15000132
**Age** Not Given **DOB** Not Given
**Gender** Not Given
**Workorder** 15000132

**Received** 01/19/2015 11:49

---

**Sample ID** 15000132-001
**Matrix** Serum or Plasma
**Patient Name** 4125SP-POS
**Patient ID** 4125SP-POS
**Container Type** Clear vial

**Collect Dt/Tm** Not Given
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|---|---|---|---|---|
| **4125SP Rufinamide, Serum/Plasma** | | | | |
| Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) | | | | |
| Rufinamide | 50 | mcg/mL | 0.50 | ELEVATED |
| Synonym(s): Inovelon; Banzel® | | | | |
| Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily rufinamide resulted in plasma concentrations ranging from 5.0 - 48 mcg/mL (n = 74). | | | | |
| Trough plasma concentrations in groups of 129-133 patients maintained on twice-daily 400 or 800 mg doses for 3 months averaged 2.6 or 4.7 mcg/mL, respectively. | | | | |

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.